Long-Acting Human Growth Hormone Analogue by Noncovalent Albumin Binding

2018/08/31 by Henrik S. Ramírez-Andersen, Carsten Behrens, Jens Buchardt +16
Biochemistry, Genetics and Molecular Biology · Medicine · #Glycosylation and Glycoproteins Research #Growth Hormone and Insulin-like Growth Factors #Monoclonal and Polyclonal Antibodies Research

paper · doi:10.1021/acs.bioconjchem.8b00463

openalex publication_date 2018/08/31 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/29

Abstract

The present work describes a series of human growth hormone (hGH) albumin binder conjugates with an extended in vivo half-life. A broad range of different conjugates were studied by varying the albumin binder structure and conjugation site. Conjugates were conveniently obtained by reductive alkylation or by alkylation to introduced cysteines using functionalized albumin-binding side chains. In vitro and in vivo profiling provided the basis for identification of position L101C in human growth hormone as the most optimal position for conjugation, where both a sufficient level of receptor binding and a suitably long half-life could yield a molecule with potential for a once-weekly dosing regimen.

Related

• A GLP‐1 receptor agonist conjugated to an albumin‐binding domain for extended half‐life
• Ligand binding strategies of human serum albumin: How can the cargo be utilized?
• N-Glycosylation Increases the Circulatory Half-Life of Human Growth Hormone
• Toward a consensus nomenclature for ghrelin, its non‐acylated form, liver expressed antimicrobial peptide 2 and growth hormone secretagogue receptor
• A Comparative Study on Albumin-Binding Molecules for Targeted Tumor Delivery through Covalent and Noncovalent Approach